Acadia(AKR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AKR Acadia

Trading 12-23 10:38:59 EST

23.77

-0.12

-0.50%

High23.99	Low23.64	Vol131.00K
Open23.80	D1 Closing23.89	Amplitude1.47%
Mkt Cap2.84B	Tradable Cap2.83B	Total Shares119.65M
T/O3.11M	T/O Rate0.11%	Tradable Shares119.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"AKR","market":"US","secType":"STK","nameCN":"Acadia","latestPrice":23.77,"timestamp":1734968336637,"preClose":23.89,"halted":0,"volume":131000,"delay":0,"floatShares":119000000,"shares":119654906,"eps":0.104152,"marketStatus":"Trading","change":-0.12,"latestTime":"12-23 10:38:59 EST","open":23.8,"high":23.99,"low":23.64,"amount":3111665.008,"amplitude":0.01465,"askPrice":23.78,"askSize":216,"bidPrice":23.76,"bidSize":410,"shortable":3,"etf":0,"ttmEps":0.104152,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1734987600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":738475200000,"exchange":"NYSE","adjPreClose":23.89,"dividendRate":0.030711,"preHourTrading":{"tag":"盘前","latestPrice":24.055,"preClose":23.89,"latestTime":"08:00 EST","volume":64,"amount":1597.870016,"timestamp":1734958800795},"postHourTrading":{"tag":"盘后","latestPrice":23.89,"preClose":23.89,"latestTime":"16:20 EST","volume":2474112,"amount":59106506.6661,"timestamp":1734729600678},"volumeRatio":0.206096,"impliedVol":0.2759,"impliedVolPercentile":0.6693},"requestUrl":"/m/hq/s/AKR/tweets","defaultTab":"tweets","newsList":[{"id":"2492648023","title":"Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2492648023","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492648023?lang=en_us&edition=fundamental","pubTime":"2024-12-20 05:05","pubTimestamp":1734642300,"startTime":"0","endTime":"0","summary":"SAN DIEGO, December 19, 2024----Acadia Pharmaceuticals Inc.  today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Catherine Owen Adams, Chief Executive Officer will represent the Company in a session scheduled on Tuesday, January 14, 2025, at 9:00 a.m. Pacific Time / 12:00 p.m. Eastern Time.A live webcast of Acadia’s presentation will be accessible on the company’s website, Acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/DaZt3JEcRzkO_33WG4k53w--~B/aD00MTc7dz0xNDYwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/82cc83c1ff20dcc24ff70c085d2d360b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/DaZt3JEcRzkO_33WG4k53w--~B/aD00MTc7dz0xNDYwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/82cc83c1ff20dcc24ff70c085d2d360b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acadia-pharmaceuticals-present-43rd-annual-210500394.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BZ1G4Q59.USD","LU0158827948.USD","LU1720051017.SGD","BK4585","LU0795875169.SGD","HCSG","LU2271345857.HKD","LU2089284900.SGD","LU0971096721.USD","LU2347655156.SGD","LU1668664300.SGD","LU1989772923.USD","LU1074936037.SGD","AKR","BK4588","LU1363072403.SGD","LU1162221912.USD","LU2065170008.USD","LU2065171311.SGD","LU2357305700.SGD","LU0098860793.USD","ACAD","LU0314104364.USD","BK4581","LU0158827781.USD","BK4516","BK4139","LU1732799900.SGD","BK4080","LU0106261372.USD","LU0006306889.USD","BK4127","LU2023251221.USD","LU2028103732.USD","LU0225283273.USD","LU0912757837.SGD","LU2089283258.USD","LU1720051108.HKD","LU0320765646.SGD","LU0795875086.SGD","BK4231","LU1732800096.USD","LU2111349929.HKD","IE00BKVL7J92.USD","BK4137","LU0267386448.USD","LU2065171402.SGD","BK4534","LU1548497426.USD","BK4504"],"gpt_icon":0},{"id":"2492288696","title":"Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2492288696","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492288696?lang=en_us&edition=fundamental","pubTime":"2024-12-17 05:05","pubTimestamp":1734383100,"startTime":"0","endTime":"0","summary":"SAN DIEGO, December 16, 2024----Acadia Pharmaceuticals Inc.  today announced that on December 4, 2024, the Compensation Committee of Acadia’s Board of Directors  granted inducement awards consisting of non-qualified stock options to purchase 38,568 shares of common stock and 22,264 restricted stock units  to thirteen new employees under Acadia’s 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635.Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage developmen","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/_5l7gkfLFbSodGou_bp.9w--~B/aD00MTc7dz0xNDYwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/598eefe833b4fea4425ee3bc119bf5fe","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/_5l7gkfLFbSodGou_bp.9w--~B/aD00MTc7dz0xNDYwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/598eefe833b4fea4425ee3bc119bf5fe"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acadia-pharmaceuticals-reports-inducement-grants-210500020.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2095319765.USD","LU2210149790.SGD","BK4139","BK4080","ACAD","LU2210150020.SGD","LU2065170008.USD","USJW.SI","BK4231","MNQmain","QID","AKR","SQQQ","NVIW.SI","IE00B3QW5Z07.USD",".IXIC","NDAQ","IE00BGHQF748.EUR","TSYW.SI","NQmain","USAW.SI","LU2065171402.SGD","BK4588","LU2065171311.SGD","PSQ","TQQQ","BK4112","LU2065169927.USD","IE00BKPKM429.USD","BK4585","QLD","IE00B64PRP62.GBP"],"gpt_icon":1},{"id":"2491393192","title":"Analysts Offer Insights on Real Estate Companies: W. P. Carey Inc. (WPC), Acadia Realty (AKR) and EPR Properties (EPR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2491393192","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491393192?lang=en_us&edition=fundamental","pubTime":"2024-12-13 09:50","pubTimestamp":1734054622,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Real Estate sector with new ratings on W. P. Carey Inc. (WPC – Research Report), Acadia Realty (AKR – R...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-real-estate-companies-w-p-carey-inc-wpc-acadia-realty-akr-and-epr-properties-epr?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-real-estate-companies-w-p-carey-inc-wpc-acadia-realty-akr-and-epr-properties-epr?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4084","BK4234","WPC","BK4160","EPR","BK4080","BK4231","AKR"],"gpt_icon":0},{"id":"2490479817","title":"Neuren Pharmaceuticals Says Partner Acadia Completes Sale of Rare Pediatric Disease Priority Review Voucher","url":"https://stock-news.laohu8.com/highlight/detail?id=2490479817","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490479817?lang=en_us&edition=fundamental","pubTime":"2024-12-12 08:07","pubTimestamp":1733962077,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  said its Nasdaq-listed partner Acadia Pharmaceuticals completed the sale of a rare pediatric disease priority review voucher for $150 million, according to a Thursday filing with the Australian bourse.The voucher was granted by the US Food and Drug Administration after the approval of Daybue for the treatment of Rett syndrome, the filing said.The company is entitled to one-third of the proceeds under its license agreement with Acadia, according to the filing.Price : $13.42, Change: $-0.02, Percent Change: -0.15%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0345774631.USD","BK4125","BK4080","BK4231","LU0426417589.USD","LU0994945656.USD","AKR","LU0426412945.USD","NEU.AU","BK7508","BK7096","LU1043141123.HKD","AUD","LU2238339852.HKD"],"gpt_icon":0},{"id":"2490815891","title":"Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2490815891","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490815891?lang=en_us&edition=fundamental","pubTime":"2024-12-12 05:05","pubTimestamp":1733951100,"startTime":"0","endTime":"0","summary":"SAN DIEGO, December 11, 2024----Acadia Pharmaceuticals Inc.  today announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher  for $150 million before fees and expenses. As described at the time the agreement to sell was announced on November 5, 2024, Acadia is required to pay Neuren Pharmaceuticals Limited one-third of the net proceeds, pursuant to a license agreement between the companies.Acadia plans to invest proceeds from the sale of the PRV to support its commercial operations, R&D programs in central nervous system and rare disease, and future business development.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/dTEB9bptsO1yJs37HWoEyw--~B/aD00MTc7dz0xNDYwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/9d51015e4af4d1edcf805def132790ca","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/dTEB9bptsO1yJs37HWoEyw--~B/aD00MTc7dz0xNDYwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/9d51015e4af4d1edcf805def132790ca"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acadia-pharmaceuticals-announces-closing-sale-210500455.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AKR","BK4139","BK4231","BK4080","LU2065170008.USD","LU2065171311.SGD","LU2065171402.SGD","LU2065169927.USD","ACAD"],"gpt_icon":0},{"id":"2490773158","title":"Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2490773158","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490773158?lang=en_us&edition=fundamental","pubTime":"2024-12-09 22:00","pubTimestamp":1733752800,"startTime":"0","endTime":"0","summary":"– Seasoned commercial executive with more than 25 years pharmaceutical and biotech experience. SAN DIEGO, December 09, 2024----Acadia Pharmaceuticals Inc.  today announced that Thomas Andrew Garner has been appointed Chief Commercial Officer, effective today. Mr. Garner will spearhead Acadia's commercial strategy and operations, driving the Company's plans for sustained growth and expansion of its product portfolio and pipeline across U.S. and international markets. Mr. Garner will report to Catherine Owen Adams, Acadia’s CEO, and serve on the executive leadership team.\"I am honored to join Acadia in a commercial leadership role that aligns seamlessly with my experience,\" said Tom Garner. \"Acadia has two exceptional franchises in NUPLAZID and DAYBUE, both with significant growth potential, as well as an impressive pipeline that has strong commercial potential. I am particularly enthusiastic about the opportunity to launch and grow our innovative therapies in rare diseases and CNS in th","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/SmrapT1UFOOvVZf7rGWYUQ--~B/aD00MTc7dz0xNDYwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/609aa0e6adb85760c8d9e2d7d314d07e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/SmrapT1UFOOvVZf7rGWYUQ--~B/aD00MTc7dz0xNDYwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/609aa0e6adb85760c8d9e2d7d314d07e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acadia-pharmaceuticals-appoints-thomas-garner-140000435.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","AKR","LU2065171311.SGD","ACAD","BK4080","LU2065171402.SGD","BMS","LU2065170008.USD","LU2065169927.USD","BK4231"],"gpt_icon":0},{"id":"2489746232","title":"Acadia Realty Trust Is Maintained at Hold by Truist Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2489746232","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489746232?lang=en_us&edition=fundamental","pubTime":"2024-12-06 00:41","pubTimestamp":1733416860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AKR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 05, 2024 11:41 ET (16:41 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","AKR","BK4231"],"gpt_icon":0},{"id":"2489453190","title":"ACADIA Realty Trust : Truist Securities Raises Target Price to $27 From $23","url":"https://stock-news.laohu8.com/highlight/detail?id=2489453190","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489453190?lang=en_us&edition=fundamental","pubTime":"2024-12-05 20:42","pubTimestamp":1733402558,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241205:nFWN3N615X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4231","BK4080","AKR"],"gpt_icon":0},{"id":"2489430416","title":"Truist Raises Price Target on Acadia Realty Trust to $27 From $23, Keeps Hold Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2489430416","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489430416?lang=en_us&edition=fundamental","pubTime":"2024-12-05 20:10","pubTimestamp":1733400646,"startTime":"0","endTime":"0","summary":"Acadia Realty Trust (AKR) has an average rating of overweight and mean price target of $27.50, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AKR"],"gpt_icon":0},{"id":"2486485686","title":"Acadia Pharmaceuticals in Exclusive License Agreement With Saniona for SAN711","url":"https://stock-news.laohu8.com/highlight/detail?id=2486485686","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486485686?lang=en_us&edition=fundamental","pubTime":"2024-11-27 07:07","pubTimestamp":1732662420,"startTime":"0","endTime":"0","summary":"Acadia Pharmaceuticals on Tuesday said it entered into an exclusive worldwide license agreement with Saniona to develop and commercialize SAN711.Acadia said it initially plans to develop SAN711 for essential tremor, a neurological condition that includes shaking or trembling in the body. The company said it plans to initiate a Phase 2 study of SAN711 in essential tremor in 2026.Under the terms of the, Saniona would receive an upfront payment of $28 million, with potential milestone payments of up to $582 million. Saniona is eligible to receive tiered royalties of up to $435 million, Acadia said.Catherine Owen Adams, Acadia's chief executive officer, said essential tremor is a condition that has not seen innovation in treatment for decades.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065170008.USD","LU2065171311.SGD","BK4231","BK4080","LU2065169927.USD","AKR","BK4139","ACAD","LU2065171402.SGD"],"gpt_icon":0},{"id":"2486485393","title":"Acadia signs licensing deal for essential tremor drug candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2486485393","media":"seekingalpha","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486485393?lang=en_us&edition=fundamental","pubTime":"2024-11-27 06:26","pubTimestamp":1732659976,"startTime":"0","endTime":"0","summary":"designer491/iStock via Getty Images Acadia Pharmaceuticals  has entered into an exclusive global licensing deal with Danish drug developer Saniona to develop and commercialize Saniona's drug candidate SAN711 for the treatment of essential tremor.  Under the deal, Saniona will receive $28M upfront plus up to $582M in","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/485688234/image_485688234.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/485688234/image_485688234.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4337482-acadia-signs-licensing-deal-for-essential-tremor-drug-candidate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":[".IXIC","LU2065170008.USD","LU2065171311.SGD","QID","LU2065171402.SGD","PSQ","MNQmain","AKR","TQQQ","BK4080","NQmain","BK4231","SQQQ","QLD","BK4139","LU2065169927.USD","ACAD"],"gpt_icon":0},{"id":"2486783078","title":"Acadia Pharmaceuticals Licenses Saniona's SAN711 for $28 Million Upfront","url":"https://stock-news.laohu8.com/highlight/detail?id=2486783078","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486783078?lang=en_us&edition=fundamental","pubTime":"2024-11-27 06:08","pubTimestamp":1732658892,"startTime":"0","endTime":"0","summary":"Acadia Pharmaceuticals  said Tuesday it will pay Saniona $28 million as part of an exclusive worldwide license agreement for the development and commercialization of SAN711 to treat rare neuropathic disorders and absence seizures.Under the agreement, Acadia will also pay Saniona up to $582 million in milestone payments as well as tiered royalties.Acadia said it will lead the development, regulatory and commercialization efforts of SAN711 and provide support for additional studies.Price: 16.06, Change: -0.15, Percent Change: -0.93","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AKR","BK4139","BK4231","BK4080","LU2065170008.USD","LU2065171311.SGD","LU2065171402.SGD","LU2065169927.USD","ACAD"],"gpt_icon":0},{"id":"2486834233","title":"Acadia announces exclusive license agreement with Saniona for SAN711","url":"https://stock-news.laohu8.com/highlight/detail?id=2486834233","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486834233?lang=en_us&edition=fundamental","pubTime":"2024-11-27 05:15","pubTimestamp":1732655711,"startTime":"0","endTime":"0","summary":"Acadia Pharmaceuticals (ACAD) Inc. announced it has entered into an exclusive worldwide license agreement with Saniona for the development and comm...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/acadia-announces-exclusive-license-agreement-with-saniona-for-san711?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/acadia-announces-exclusive-license-agreement-with-saniona-for-san711?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4080","BK4139","LU2065169927.USD","LU2065170008.USD","LU2065171311.SGD","ACAD","AKR","BK4231","LU2065171402.SGD"],"gpt_icon":0},{"id":"2486250834","title":"Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711","url":"https://stock-news.laohu8.com/highlight/detail?id=2486250834","media":"Business Wire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486250834?lang=en_us&edition=fundamental","pubTime":"2024-11-27 05:05","pubTimestamp":1732655100,"startTime":"0","endTime":"0","summary":"- SAN711 is a first-in-class, highly selective GABAA-α3 positive allosteric modulator. - Targeting initiation of Phase 2 study of SAN711 for the treatment of essential tremor in 2026. SAN DIEGO, November 26, 2024----Acadia Pharmaceuticals Inc.  today announced it has entered into an exclusive worldwide license agreement with Saniona  for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. The first indication the Company plans to pursue is development of SAN711 for essential tremor, a neurological condition that includes shaking or trembling movements in one or more parts of the body. Acadia is planning to initiate a Phase 2 study of SAN711 in essential tremor in 2026.\"Licensing SAN711 to expand our pipeline underscores our unwavering commitment to delivering innovative therapies for patients with central nervous system disorders,\" said Catherine Owen Adams, Chief Executive Officer. \"Essential tremor is a condition","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/gw4IGZjH755fiGoLalTcHA--~B/aD00MTc7dz0xNDYwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/054c045bcb6a486434a5ae26df77996b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/gw4IGZjH755fiGoLalTcHA--~B/aD00MTc7dz0xNDYwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/054c045bcb6a486434a5ae26df77996b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acadia-pharmaceuticals-announces-exclusive-license-210500320.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2065169927.USD","BK4139","ACAD","AKR","LU2065171402.SGD","BK4080","LU2065170008.USD","BK4231","LU2065171311.SGD"],"gpt_icon":0},{"id":"2485232584","title":"Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2485232584","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485232584?lang=en_us&edition=fundamental","pubTime":"2024-11-22 05:05","pubTimestamp":1732223100,"startTime":"0","endTime":"0","summary":"SAN DIEGO, November 21, 2024----Acadia Pharmaceuticals Inc.  today announced that it will participate at two upcoming investor conferences:. Citi's 2024 Global Healthcare ConferenceFireside Chat: Tuesday, December 3, 2024 at 10:15 a.m. Eastern Time in Miami, FL. 7th Annual Evercore HealthCONx ConferenceFireside Chat: Wednesday, December 4, 2024 at 2:35 p.m. Eastern Time in Coral Gables, FL. Live webcasts of each fireside chat will be accessible on the company’s website, Acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following each presentation.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ZFqVfxsQi4s1Pj74jcHZYQ--~B/aD00MTc7dz0xNDYwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/bbed4ddd2fe6c84d9d6d40dba032e493","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ZFqVfxsQi4s1Pj74jcHZYQ--~B/aD00MTc7dz0xNDYwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/bbed4ddd2fe6c84d9d6d40dba032e493"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acadia-pharmaceuticals-participate-upcoming-investor-210500525.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ACAD","LU2065169927.USD","LU2065171402.SGD","BK4139","LU2065170008.USD","LU2065171311.SGD","BK4080","BK4231","AKR"],"gpt_icon":0},{"id":"2485517467","title":"Acadia Pharmaceuticals Terminates COO Brendan Teehan","url":"https://stock-news.laohu8.com/highlight/detail?id=2485517467","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485517467?lang=en_us&edition=fundamental","pubTime":"2024-11-21 06:21","pubTimestamp":1732141283,"startTime":"0","endTime":"0","summary":"Acadia Pharmaceuticals  said in a late Wednesday filing that Chief Operating Officer Brendan Teehan will be involuntarily terminated without cause, effective immediately.Chief Executive Catherine Adams will assume responsibilities of the COO role until a successor is appointed, the company said.Teehan will remain with the company as a non-executive employee until Dec. 31, the company added.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2065170008.USD","LU2065171311.SGD","LU2272731600.USD","BK4139","ACAD","LU2065171402.SGD","AKR","BK4080","BK4198","BK4231","LU2272731782.SGD","LU2065169927.USD","GB00BDT5M118.USD","LU1992135472.HKD","COO","LU2211815571.USD","BK4585","BK4588","LU1992135399.USD"],"gpt_icon":0},{"id":"2485746711","title":"Acadia Pharmaceuticals' Operating Chief Involuntarily Terminated Without Cause","url":"https://stock-news.laohu8.com/highlight/detail?id=2485746711","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485746711?lang=en_us&edition=fundamental","pubTime":"2024-11-21 06:20","pubTimestamp":1732141200,"startTime":"0","endTime":"0","summary":"Acadia Pharmaceuticals reached an agreement with Operating Chief Brendan Teehan in which he would be involuntarily terminated without cause, according to a regulatory filing.Teehan, who additionally served as head of commercial and an executive vice president, will remain employed as a non-executive employee through the end of the year to assist with the succession and transition, the San Diego company said in a Securities and Exchange Commission filing Wednesday.The company's top executive, Catherine Owen Adams, will assume Teehan's responsibilities until a successor is appointed.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACAD","AKR"],"gpt_icon":0},{"id":"2485711001","title":"BRIEF-Acadia Pharmaceuticals Inc - On Nov 18, Co Involuntarily Terminates COO Brendan Teehan","url":"https://stock-news.laohu8.com/highlight/detail?id=2485711001","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485711001?lang=en_us&edition=fundamental","pubTime":"2024-11-21 06:08","pubTimestamp":1732140522,"startTime":"0","endTime":"0","summary":"Nov 20 (Reuters) - ACADIA Pharmaceuticals Inc   :   * ACADIA PHARMACEUTICALS INC - ON NOV 18, CO INVOLUNTARILY TERMINATES COO BRENDAN TEEHANSource text: [ Further company coverage:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861219969.SGD","LU2065171311.SGD","LU0348723411.USD","ACAD","LU1992135472.HKD","LU0724618433.USD","GB00BDT5M118.USD","LU2065169927.USD","IE00BD6J9T35.USD","BK4139","LU2065171402.SGD","LU2360107325.USD","BK4585","LU2357305700.SGD","LU1861220033.SGD","IE00BZ199S13.USD","COO","BK4141","BK4080","LU1992135399.USD","BK4512","LU2298322129.HKD","LU2272731782.SGD","LU2065170008.USD","LU1861215975.USD","AKR","LU1854103824.USD","LU2272731600.USD","LU1548497426.USD","LU1861214812.USD","BK4231","LU1720051108.HKD","LU1720051017.SGD","ON","BK4198","LU1854104046.USD","LU1978683503.SGD","LU2211815571.USD","LU0124384867.USD","BK4588"],"gpt_icon":0},{"id":"2485171787","title":"Acadia Pharmaceuticals Announces Leadership Change Amid COO Departure","url":"https://stock-news.laohu8.com/highlight/detail?id=2485171787","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485171787?lang=en_us&edition=fundamental","pubTime":"2024-11-21 05:55","pubTimestamp":1732139746,"startTime":"0","endTime":"0","summary":"An update from ACADIA Pharmaceuticals ( ($ACAD) ) is now available. Acadia Pharmaceuticals Inc. announced the involuntary termination of Brendan Te...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/acadia-pharmaceuticals-announces-leadership-change-amid-coo-departure?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/acadia-pharmaceuticals-announces-leadership-change-amid-coo-departure?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","LU2272731782.SGD","BK4080","LU1992135399.USD","BK4231","LU2272731600.USD","COO","BK4198","LU2211815571.USD","AKR","LU1992135472.HKD","GB00BDT5M118.USD"],"gpt_icon":0},{"id":"2483533616","title":"Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2483533616","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483533616?lang=en_us&edition=fundamental","pubTime":"2024-11-16 05:05","pubTimestamp":1731704700,"startTime":"0","endTime":"0","summary":"SAN DIEGO, November 15, 2024----Acadia Pharmaceuticals Inc.  today announced that on November 8, 2024, the Compensation Committee of Acadia’s Board of Directors  granted inducement awards consisting of non-qualified stock options to purchase 70,571 shares of common stock and 40,731 restricted stock units  to twenty-three new employees under Acadia’s 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635.Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage develo","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Hyskoq8XYdgIDgKCV82ZjA--~B/aD00MTc7dz0xNDYwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/928bb1591963cc1a54a2d0387b90a2bb","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Hyskoq8XYdgIDgKCV82ZjA--~B/aD00MTc7dz0xNDYwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/928bb1591963cc1a54a2d0387b90a2bb"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acadia-pharmaceuticals-reports-inducement-grants-210500812.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4080","IE00BGHQF748.EUR","BK4139","LU2065169927.USD","TQQQ","QID","IE00B64PRP62.GBP","LU2210150020.SGD","LU2065170008.USD","AKR","LU2065171311.SGD","LU2065171402.SGD","IE00B3QW5Z07.USD","QLD",".IXIC","ACAD","NQmain","MNQmain","IE00BKPKM429.USD","LU2210149790.SGD","SQQQ","BK4588","BK4231","PSQ","BK4112","LU2095319765.USD","BK4585","NDAQ"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.acadiarealty.com","stockEarnings":[{"period":"1week","weight":-0.0576},{"period":"1month","weight":-0.0425},{"period":"3month","weight":0.052},{"period":"6month","weight":0.3769},{"period":"1year","weight":0.4103},{"period":"ytd","weight":0.4061}],"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0403},{"period":"6month","weight":0.0857},{"period":"1year","weight":0.2506},{"period":"ytd","weight":0.2437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Acadia Realty Trust is an equity real estate investment trust focused on delivering long-term, profitable growth via its dual  Core Portfolio and Fund  operating platforms and its disciplined, location-driven investment strategy. Acadia Realty Trust is accomplishing this goal by building a best-in-class core real estate portfolio with meaningful concentrations of assets in the nation's most dynamic corridors; making profitable opportunistic and value-add investments through its series of discretionary, institutional funds; and maintaining a strong balance sheet.","yearOnYearQuotes":[{"month":1,"riseRate":0.645161,"avgChangeRate":0.023058},{"month":2,"riseRate":0.483871,"avgChangeRate":0.005073},{"month":3,"riseRate":0.645161,"avgChangeRate":-0.002898},{"month":4,"riseRate":0.483871,"avgChangeRate":0.015318},{"month":5,"riseRate":0.387097,"avgChangeRate":-0.006365},{"month":6,"riseRate":0.53125,"avgChangeRate":0.004318},{"month":7,"riseRate":0.59375,"avgChangeRate":0.016731},{"month":8,"riseRate":0.46875,"avgChangeRate":-0.004467},{"month":9,"riseRate":0.40625,"avgChangeRate":-0.006555},{"month":10,"riseRate":0.53125,"avgChangeRate":-0.003012},{"month":11,"riseRate":0.5,"avgChangeRate":0.010973},{"month":12,"riseRate":0.34375,"avgChangeRate":-0.008573}],"exchange":"NYSE","name":"Acadia","nameEN":"Acadia"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Acadia(AKR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Acadia(AKR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Acadia,AKR,Acadia股票,Acadia股票老虎,Acadia股票老虎国际,Acadia行情,Acadia股票行情,Acadia股价,Acadia股市,Acadia股票价格,Acadia股票交易,Acadia股票购买,Acadia股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Acadia(AKR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Acadia(AKR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction